Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kina vs OlleveCare

Kina
Graded #107

Higher grade

vs+23.89999999999999
OlleveCare
Graded #497

Lower grade

The verdict

Kina takes it — 70.1/100 to 46.2/100.

Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKina +16
61
45
Dose & formulationKina +24
64
40
Clinical oversightKina +35
88
53
Labs & monitoringKina +15
64
49
FulfillmentKina +45
83
38
Contract termsKina +6
61
55
Kina · left barOlleveCare · right bar

The numbers

MetricKinaOlleveCare
WeighScore70.1/10046.2/100
GradeCC
Scorecard rank#107#497
Semaglutide$179/mo (starting dose, plus a separate fee, compounded)Not disclosed
Tirzepatide$179/mo (starting dose, compounded)Not disclosed
CoverageCoverage not published13 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Kina

Graded #107 · C

Strengths

  • Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
  • Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
  • Verifiable LegitScript certification (seal ID 50917967)
  • GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
  • Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Built for women navigating menopause — less tailored if that is not your situation
  • A separate $50 physician consultation fee applies on top of the medication price
  • The compounding pharmacy partner is not named, and the full list of served states is not published
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard